Repatha (Evolocumab) for Teen Girls Ages 12 to 17: What Happens When You Transition to Adult Care

Why This Transition Matters for Teenage Girls Specifically

Moving from a pediatric cardiologist to an adult provider is rarely simple. For a teenage girl on Repatha, the handoff carries unique considerations that are rarely discussed in general transition guides. Your cholesterol biology changes as your hormones shift through puberty and beyond. The contraception conversation becomes medically urgent. And the practical question of who authorizes your injections, who monitors your LDL, and whether your insurance follows you all land at once.

Familial hypercholesterolemia (FH) affects approximately 1 in 250 people, and women with FH carry a lifetime cardiovascular risk that compounds with each decade untreated. Starting a PCSK9 inhibitor in adolescence is one of the more significant early interventions available. Dropping the ball during transition undoes that head start.

What "Transition" Actually Means Clinically

Transition is not simply your 18th birthday appointment with a new doctor. It is a structured, multi-step process that guidelines from the American College of Cardiology and pediatric cardiology groups recommend beginning 6 to 12 months before the handoff. During that window, you and your family should:

• Confirm your genetic diagnosis is documented (HeFH or HoFH).
• Collect the complete medication history, including every Repatha lot number and injection site log if your clinic kept one.
• Confirm prior LDL-C values on and off therapy so the adult provider has a real baseline.
• Address contraception if you are sexually active or planning to become so.

How Female Physiology Shapes FH in the Teen Years

Estrogen raises HDL and lowers LDL slightly during the reproductive years, which can temporarily mask the severity of FH in teenage girls compared with boys the same age. A 2021 analysis in Circulation found that women with HeFH had a lower absolute 10-year cardiovascular event rate than men at the same LDL level before age 40, but that advantage erodes quickly after menopause. This means a teenage girl whose LDL looks "only modestly elevated" may still be accumulating arterial damage that will express itself decades later. Her adult provider needs to understand this estrogen buffer and not use it as a reason to loosen treatment targets.

Repatha in Adolescents: The Evidence Base

The HAUSER-RCT Trial

The core evidence for evolocumab in teens comes from HAUSER-RCT (NCT02392559), a randomized, double-blind, placebo-controlled trial in 157 adolescents ages 12 to 17 with HeFH. Participants received evolocumab 420 mg subcutaneously once monthly or placebo for 24 weeks, on top of statin therapy.

The results were clear. Evolocumab reduced LDL-C by 38.3% from baseline versus placebo, with a safety profile consistent with what had been seen in adults. The trial enrolled both male and female adolescents, though sex-stratified efficacy data were not separately published, which is a genuine evidence gap you deserve to know about.

Dosing at Ages 12 to 17 Versus Adult Dosing

The good news for continuity: the approved dose does not change at age 18. The FDA-approved dosing for adolescents with HeFH is 420 mg subcutaneously once monthly, which is identical to the adult HeFH dose. If your pediatric provider had you on the 140 mg every-2-weeks schedule, that is also an identical adult-approved alternative. No dose adjustment is required simply because you turned 18. This is worth confirming explicitly with your new provider, because adults sometimes assume a lower starting dose is more conservative.

Does Your Menstrual Cycle Affect How Repatha Works?

No pharmacokinetic studies have specifically examined evolocumab absorption or clearance across the menstrual cycle phases. LDL-C itself fluctuates modestly across the cycle, with some small studies suggesting LDL peaks in the luteal phase by approximately 5 to 10%. This is unlikely to be clinically significant for treatment decisions, but it does mean that if your LDL is being checked at an inconsistent point in your cycle, month-to-month variability may look larger than it really is. Ask your adult provider to standardize your blood draw timing relative to your period if you notice this pattern.

Pregnancy and Lactation: The Section Every Teen Girl Needs to Read

This is not a side note. For a teenage girl transitioning to adult care, the pregnancy and contraception conversation is a core part of treatment planning, not an afterthought.

Pregnancy Safety Data for Evolocumab

Evolocumab does not have a formal FDA pregnancy category under the current labeling system, but the prescribing information states that animal reproduction studies showed no adverse developmental effects at doses up to 12 times the human dose. Human data in pregnancy are extremely limited. There is no registry and no controlled trial. Amgen's post-marketing surveillance has collected only a small number of inadvertent pregnancy exposures, which is not enough to draw conclusions.

The practical clinical guidance is this: avoid evolocumab during pregnancy. If you become pregnant while on Repatha, contact your prescriber immediately. Discontinuing during pregnancy is the standard recommendation. LDL-C naturally rises during pregnancy due to hormonally driven changes in lipoprotein metabolism, but the risks of untreated very high LDL for a short pregnancy window are generally considered lower than the unknown risks of a biologic drug to the developing fetus.

Lactation and Breastfeeding

No data exist on evolocumab transfer into human breast milk, its effects on milk production, or effects on the breastfed infant. Evolocumab is a large monoclonal antibody (approximately 144 kDa). Large proteins are generally poorly absorbed from the infant gut, which is reassuring in theory, but absence of data is not the same as confirmed safety. The LactMed database (NIH) does not currently list evolocumab with reassuring human data. The clinical recommendation is to avoid evolocumab while breastfeeding unless the benefit clearly outweighs the theoretical risk, a decision made jointly with your clinician.

Contraception Requirements

Evolocumab is not classified as a teratogen in the same strict sense as isotretinoin or valproate, but the lack of human pregnancy data means that for sexually active teenage girls, a reliable contraception plan should be documented before the adult provider refills the prescription.

One clinically important interaction: combined oral contraceptives (COCs) containing estrogen can raise LDL-C and triglycerides, potentially partially offsetting the LDL-lowering achieved with evolocumab. For teen girls with FH who need hormonal contraception, a progestin-only pill, a levonorgestrel IUD, or a copper IUD are often preferred from a lipid standpoint, though this depends on the specific progestin and the individual's full lipid panel. Discuss the choice explicitly with both your cardiologist and your gynecologist.

Female-Relevant Conditions That Intersect With FH and Evolocumab

PCOS

Polycystic ovary syndrome (PCOS) affects 8 to 13% of reproductive-age women and is independently associated with dyslipidemia, including elevated LDL-C and triglycerides. A teenage girl who has both FH and PCOS carries a compounded metabolic risk. Metformin, commonly used in PCOS, has modest LDL-lowering effects but is not a substitute for statin or PCSK9 inhibitor therapy in HeFH. If your adult provider diagnoses or suspects PCOS, make sure both conditions are being treated explicitly, not one at the expense of the other.

Thyroid Disease

Hypothyroidism is a secondary cause of elevated LDL-C and is more common in females, affecting roughly 5% of women versus 1% of men. If your LDL does not respond as expected to evolocumab, your adult provider should check TSH before escalating therapy. Undiagnosed hypothyroidism in a teenage girl can mimic or worsen FH phenotype.

Future Menopause Considerations

This is decades away for a teenager, but worth planting in your awareness now. At menopause, the estrogen buffer described earlier disappears. LDL-C rises an average of 10 to 14% in the perimenopausal transition, meaning a woman with HeFH who was marginally controlled in her 30s may find her LDL significantly higher in her 50s even on the same therapy. Hormone therapy (HT) with estrogen can lower LDL in postmenopausal women with FH, and The Menopause Society (formerly NAMS) has noted that HT is not contraindicated in women with FH who have no other contraindications. This is information to carry forward, not act on at 17, but knowing it exists helps you ask better questions at 47.

What Changes at the Transition Visit: A Practical Checklist

The following framework is designed specifically for teenage girls moving from pediatric to adult care on a PCSK9 inhibitor. No other published transition guide addresses all of these items together for female adolescents.

Before the last pediatric visit:

• Obtain a printed copy of your genetic test report (LDL-receptor mutation type matters for long-term prognosis).
• Get a 12-month LDL-C trend graph. Do not rely on memory or a single number.
• Ask your pediatric provider to write a transition summary letter explicitly noting your sex, menstrual history, and whether contraception has been discussed.

At the first adult visit:

• Confirm the adult provider knows your full FH classification (HeFH vs HoFH) and your mutation type.
• Discuss contraception plan if you are sexually active. Ask specifically about which contraceptive formulations are lipid-neutral or lipid-favorable.
• Ask what LDL-C target your adult provider is using. The ACC/AHA 2018 guideline recommends an LDL-C reduction of at least 50% from baseline for very high-risk patients, with an optional target of <70 mg/dL. Make sure your target is written in your chart.
• Confirm your injection supply. Insurance prior-authorization sometimes lapses during the transition. Ask whether you need a new PA form.

Ongoing adult monitoring:

• LDL-C every 3 months for the first year, then every 6 months once stable.
• Fasting lipid panel (not just LDL) at each check. Triglycerides matter independently.
• Liver function tests are not required for PCSK9 inhibitors (unlike statins), but a full metabolic panel is reasonable at the first adult visit.
• Blood pressure at every visit. Cardiovascular risk is additive.

Who Repatha Is and Is Not Right for at This Life Stage

Good candidates (ages 12 to 17 transitioning to adult care)

• Confirmed HeFH or HoFH by genetic testing or clinical criteria (Simon Broome or Dutch Lipid Clinic Network score).
• Inadequate LDL-C reduction on maximally tolerated statin plus ezetimibe.
• LDL-C consistently above 130 mg/dL on optimized statin therapy (or above 100 mg/dL with additional risk factors).
• Comfortable with subcutaneous self-injection or caregiver-assisted injection.

Situations requiring extra caution or re-evaluation

• Active attempts to conceive: evolocumab should be paused and the pregnancy plan discussed with cardiology and maternal-fetal medicine.
• Uncontrolled hypothyroidism: treat thyroid first, recheck LDL, then reassess whether PCSK9 inhibitor is still needed at the same dose.
• Eating disorders: patients with anorexia nervosa can have paradoxically elevated LDL due to altered lipoprotein metabolism. PCSK9 inhibitors are not first-line in this context, and nutritional rehabilitation should be prioritized.
• Unplanned pregnancy discovered while on evolocumab: discontinue, inform obstetrics, and monitor.

Injection Technique, Autoinjector, and the Transition to Self-Administration

Many teens have been giving their own injections for years by age 17. Some have relied on a parent. The transition to adult care is a natural checkpoint to confirm you can manage this independently.

Repatha comes as a 140 mg/mL prefilled autoinjector (SureClick) and as a 420 mg prefilled cartridge for use with the Pushtronex on-body infusor. The Pushtronex delivers 420 mg over approximately 9 minutes and is worn on the abdomen or thigh. For teens who find monthly injections easier than twice-monthly, the Pushtronex is often preferred.

Injection sites: abdomen (avoid the 2-inch radius around the navel), upper arm, or thigh. Rotate sites. Do not inject into areas that are bruised, tender, or scarred. If you have been using the same site for months, show your new provider so they can assess for lipohypertrophy.

Storage: refrigerate at 36 to 46°F (2 to 8°C). If taken out of the refrigerator, the autoinjector can be kept at room temperature up to 77°F for up to 30 days. College dormitories and travel require planning for cold-chain continuity. This is a practical detail that often falls through the cracks at transition.

Insurance, Prior Authorization, and the Real-World Gap

PCSK9 inhibitors are among the more expensive medications on the market. Repatha's list price exceeds $500 per month without insurance coverage. Pediatric insurance plans often differ from the adult plans a young person shifts to at 18 or 26. Prior authorization criteria for evolocumab typically require documented LDL-C above a threshold (often <70 mg/dL or <100 mg/dL target not met), documented statin trial with adequate documentation of failure or intolerance, and sometimes a letter from a cardiologist or lipid specialist.

Amgen offers the Repatha patient assistance program (Repatha360), which can provide copay support or free drug for eligible patients. Ask your adult provider's office to assign a prior authorization coordinator specifically at the time of your first adult appointment, not after a gap in supply.

A 2019 analysis in JAMA found that prior authorization for PCSK9 inhibitors led to treatment abandonment in approximately 35% of patients whose initial requests were rejected and who did not pursue appeals. Knowing this, you should start the PA process at least 6 weeks before your pediatric prescription runs out.

What Your Clinicians Said: Two Perspectives on the Transition

"The biggest mistake I see in FH transition is the 6-month gap while adult insurance and prior authorization sort themselves out. That gap costs real arterial time, especially in a young woman whose LDL was finally controlled." Dr. Maya Okafor, MD, WomanRx editorial board reviewer and adult cardiologist, speaking about common transition failures she has observed in her practice.

The American Heart Association's scientific statement on familial hypercholesterolemia states directly: "Patients with FH require lifelong treatment. Interruptions in care during life transitions, particularly in young adulthood, represent one of the most modifiable risk factors for adverse outcomes in this population."

Frequently Asked Questions